President & Chief Executive Officer
Over a 30+ year career, Richard has demonstrated particular strengths in new product development & commercialization, clinical research & regulatory affairs, & start-up management. Prior to joining Endomedix, Richard was President & CEO of OST Développement SA, a French subsidiary of a NASDAQ firm, Osteotech, Inc. Starting from a base of virtually no customers, OST quickly built a $24M business by restructuring the practice of bone grafting in countries in Europe, Asia & Latin America. Richard was also a seed investor & manager in Meditron Corporation which successfully developed a class III device & was acquired by Cross Medical. Prior to Meditron, he was a manager of a small public company, Electro-Biology Inc., which was acquired by Biomet. Richard has also worked at major firms such as Baxter International, C.R bard & American Sterilizer Co. in positions of progressively increasing responsibilities. Richard joined Endomedix in 2009 as President and Chief Executive Officer. Since he arrived, Richard redirected the Company from its original business model and business strategy; negotiated the cancellation of a licensing agreement with Integra Life Sciences; re-established the laboratory and the Company’s product development team; led the IP program that has produced 7 issued patents in US, Canada and Europe; and led the development of its current technology platform. In addition to his position as President and Chief Executive Officer, Richard serves on the Board of Directors. Richard earned a BA cum laude at Boston College and a MBA at Columbia Business School.